Citations

Clear

153 citation(s) found for "Thomas, Michael".

Enhancing the Trustworthiness of the Endocrine Society’s Clinical Practice Guidelines
McCartney, Christopher R. , Corrigan, Maureen D. , Drake, Matthew T. , Fuleihan, Ghada El‐Hajj , Korytkowski, Mary T. , Lash, Robert W. , Lieb, David C. , McCall, Anthony L. , Muniyappa, Ranganath , Piggott, Thomas , Schünemann, Holger J. , El-Hajj Fuleihan, Ghada , Schünemann, Holger J , Wiercioch, Wojtek , McDonnell, Marie E , Murad, M Hassan , Drake, Matthew T , Muniyappa, Ranganath , McCartney, Christopher R , Piggott, Thomas , Santesso, Nancy A. , Wiercioch, Wojtek , McDonnell, Marie E. , Murad, M. Hassan

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | June 12, 2022 | Volume: 107 | Issue: 8 | Pages: 2129-2138

10.1210/clinem/dgac290 | PMID 35690966 Get It

Abstract In an effort to enhance the trustworthiness of its clinical practice guidelines, the Endocrine Society has recently adopted new policies and more rigorous methodologies for its guideline program. In this Clinical Practice Guideline Communication, we describe these recent enhancements—many of which reflect greater adherence to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach to guideline development—in addition to the rationale for such changes. Improvements to the Society’s guideline development practices include, but are not limited to, enhanced inclusion of nonendocrinologist experts, including patient representatives, on guideline development panels; implementation of a more rigorous conflict/duality of interest policy; a requirement that all formal recommendations must be demonstrably underpinned by systematic evidence review; the explicit use of GRADE Evidence-to-Decision frameworks; greater use and explanation of standardized guideline language; and a more intentional approach to guideline updating. Lastly, we describe some of the experiential differences our guideline readers are most likely to notice.
Protocol for multicentre comparison of interictal high-frequency oscillations as a predictor of seizure freedom
Dimakopoulos, Vasileios , Gotman, Jean , Stacey, William C. , Jacobs, Julia , Papadelis, Christos , Sperling, Michael R. , Zijlmans, Maike, Imbach, Lucas, Sarnthein, Johannes , Stacey, William , Papadelis, Christos , Sarnthein, Johannes , Sperling, Michael R , Ellenrieder, Nicolás von , Cimbálník, Jan , Worrell, Gregory A. , Frauscher, Birgit

Mayo Clinic

Brain Communications | June 9, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1093/braincomms/fcac151 | PMID 35770134 Get It

Abstract In drug-resistant focal epilepsy, interictal high-frequency oscillations (HFOs) recorded from intracranial EEG (iEEG) may provide clinical information for delineating epileptogenic brain tissue. The iEEG electrode contacts that contain HFO are hypothesized to delineate the epileptogenic zone; their resection should then lead to postsurgical seizure freedom. We test whether our prospective definition of clinically relevant HFO is in agreement with postsurgical seizure outcome. The algorithm is fully automated and is equally applied to all data sets. The aim is to assess the reliability of the proposed detector and analysis approach. We use an automated data-independent prospective definition of clinically relevant HFO that has been validated in data from two independent epilepsy centres. In this study, we combine retrospectively collected data sets from nine independent epilepsy centres. The analysis is blinded to clinical outcome. We use iEEG recordings during NREM sleep with a minimum of 12 epochs of 5 min of NREM sleep. We automatically detect HFO in the ripple (80–250 Hz) and in the fast ripple (250–500 Hz) band. There is no manual rejection of events in this fully automated algorithm. The type of HFO that we consider clinically relevant is defined as the simultaneous occurrence of a fast ripple and a ripple. We calculate the temporal consistency of each patient’s HFO rates over several data epochs within and between nights. Patients with temporal consistency <50% are excluded from further analysis. We determine whether all electrode contacts with high HFO rate are included in the resection volume and whether seizure freedom (ILAE 1) was achieved at ≥2 years follow-up. Applying a previously validated algorithm to a large cohort from several independent epilepsy centres may advance the clinical relevance and the generalizability of HFO analysis as essential next step for use of HFO in clinical practice.
Drug Interactions Affecting Oral Anticoagulant Use
Mar, Philip L. , Gopinathannair, Rakesh , Gengler, Brooke , Chung, Mina K. , Perez, Arturo, Dukes, Jonathan W., Ezekowitz, Michael D. , Lakkireddy, Dhanunjaya , Miletello, Mike, Reiffel, James A. , Gengler, Brooke E , Lip, Gregory Y H , Miletello, Mike , Noseworthy, Peter A , Reiffel, James A , Tisdale, James E , Olshansky, Brian , Gopinathannair, Rakesh , Noseworthy, Peter A. , Olshansky, Brian

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | May 27, 2022 | Volume: 15 | Issue: 6 | Pages: No page available

10.1161/circep.121.007956 | PMID 35622425 Get It

Oral anticoagulants (OACs) are medications commonly used in patients with atrial fibrillation and other cardiovascular conditions. Both warfarin and direct oral anticoagulants are susceptible to drug-drug interactions (DDIs). DDIs are an important cause of adverse drug reactions and exact a large toll on the health care system. DDI for warfarin mainly involve moderate to strong inhibitors/inducers of cytochrome P450 (CYP) 2C9, which is responsible for the elimination of the more potent S-isomer of warfarin. However, inhibitor/inducers of CYP3A4 and CYP1A2 may also cause DDI with warfarin. Recognition of these precipitating agents along with increased frequency of monitoring when these agents are initiated or discontinued will minimize the impact of warfarin DDI. Direct oral anticoagulants are mainly affected by medications strongly affecting the permeability glycoprotein (P-gp), and to a lesser extent, strong CYP3A4 inhibitors/inducers. Dabigatran and edoxaban are affected by P-gp modulation. Strong inducers of CYP3A4 or P-gp should be avoided in all patients taking direct oral anticoagulant unless previously proven to be otherwise safe. Simultaneous strong CYP3A4 and P-gp inhibitors should be avoided in patients taking apixaban and rivaroxaban. Concomitant antiplatelet/anticoagulant use confers additive risk for bleeding, but their combination is unavoidable in many cases. Minimizing duration of concomitant anticoagulant/antiplatelet therapy as indicated by evidence-based clinical guidelines is the best way to reduce the risk of bleeding.
ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions
Hirsch, Édouard , French, Jacqueline A. , Scheffer, Ingrid E. , Bogacz, Alicia, Alsaadi, Taoufik , Sperling, Michael R. , Abdulla, Fatema , Zuberi, Sameer M. , Trinka, Eugen , Specchio, Nicola , Somerville, Ernest , Riney, Kate , Nabbout, Rima , Jain, Satish, Wilmshurst, Jo M. , Wiebe, Samuel , Perucca, Emilio , Connolly, Mary , Kochen, Silvia , French, Jacqueline , Samia, Pauline , Nabbout, Rima , Wilmshurst, Jo M , Auvin, Stéphane , Wiebe, Samuel , Perucca, Emilio , Moshé, Solomon L , Wirrell, Elaine C , Sperling, Michael R , Hirsch, Edouard , Scheffer, Ingrid E , Trinka, Eugen , Somerville, Ernest , Specchio, Nicola , Zuberi, Sameer M , Samia, Pauline , Jain, Satish, Auvin, Stéphane , Moshé, Solomon L. , Tinuper, Paolo , Wirrell, Elaine

Mayo Clinic

Epilepsia | May 3, 2022 | Volume: 63 | Issue: 6 | Pages: 1475-1499

10.1111/epi.17236 | PMID 35503716 Get It

Abstract In 2017, the International League Against Epilepsy (ILAE) Classification of Epilepsies described the “genetic generalized epilepsies” (GGEs), which contained the “idiopathic generalized epilepsies” (IGEs). The goal of this paper is to delineate the four syndromes comprising the IGEs, namely childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and epilepsy with generalized tonic–clonic seizures alone. We provide updated diagnostic criteria for these IGE syndromes determined by the expert consensus opinion of the ILAE’s Task Force on Nosology and Definitions (2017–2021) and international external experts outside our Task Force. We incorporate current knowledge from recent advances in genetic, imaging, and electroencephalographic studies, together with current terminology and classification of seizures and epilepsies. Patients that do not fulfill criteria for one of these syndromes, but that have one, or a combination, of the following generalized seizure types: absence, myoclonic, tonic‐clonic and myoclonic‐tonic‐clonic seizures, with 2.5–5.5 Hz generalized spike‐wave should be classified as having GGE. Recognizing these four IGE syndromes as a special grouping among the GGEs is helpful, as they carry prognostic and therapeutic implications.
Drug Interactions Affecting Antiarrhythmic Drug Use
Mar, Philip L. , Horbal, Piotr J. , Chung, Mina K. , Dukes, Jonathan W., Ezekowitz, Michael D. , Lakkireddy, Dhanunjaya , Miletello, Mike, Noseworthy, Peter A. , Reiffel, James A. , Horbal, Piotr , Ezekowitz, Michael , Lip, Gregory Y H , Miletello, Mike , Noseworthy, Peter A , Reiffel, James A , Tisdale, James E , Olshansky, Brian , Gopinathannair, Rakesh , Dukes, Jonathan W., Olshansky, Brian , Gopinathannair, Rakesh

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | May 2, 2022 | Volume: 15 | Issue: 5 | Pages: No page available

10.1161/circep.121.007955 | PMID 35491871 Get It

Antiarrhythmic drugs (AAD) play an important role in the management of arrhythmias. Drug interactions involving AAD are common in clinical practice. As AADs have a narrow therapeutic window, both pharmacokinetic as well as pharmacodynamic interactions involving AAD can result in serious adverse drug reactions ranging from arrhythmia recurrence, failure of device-based therapy, and heart failure, to death. Pharmacokinetic drug interactions frequently involve the inhibition of key metabolic pathways, resulting in accumulation of a substrate drug. Additionally, over the past 2 decades, the P-gp (permeability glycoprotein) has been increasingly cited as a significant source of drug interactions. Pharmacodynamic drug interactions involving AADs commonly involve additive QT prolongation. Amiodarone, quinidine, and dofetilide are AADs with numerous and clinically significant drug interactions. Recent studies have also demonstrated increased morbidity and mortality with the use of digoxin and other AAD which interact with P-gp. QT prolongation is an important pharmacodynamic interaction involving mainly Vaughan-Williams class III AAD as many commonly used drug classes, such as macrolide antibiotics, fluoroquinolone antibiotics, antipsychotics, and antiemetics prolong the QT interval. Whenever possible, serious drug-drug interactions involving AAD should be avoided. If unavoidable, patients will require closer monitoring and the concomitant use of interacting agents should be minimized. Increasing awareness of drug interactions among clinicians will significantly improve patient safety for patients with arrhythmias.
Graph theoretical measures of fast ripples support the epileptic network hypothesis
Weiss, Shennan A. , Pastore, Tomás, Orosz, Iren, Waldman, Zachary, Fried, Itzhak , Wu, Chengyuan , Sharan, Ashwini , Engel, Jerome , Sperling, Michael R. , Staba, Richard J. , Wu, Chengyuan , Sperling, Michael R , Weiss, Shennan A , Rubinstein, Daniel , Gorniak, Richard , Slezak, Diego Fernández , Worrell, Gregory A.

Mayo Clinic

Brain Communications | April 14, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1093/braincomms/fcac101 | PMID 35620169 Get It

Abstract The epileptic network hypothesis and epileptogenic zone hypothesis are two theories of ictogenesis. The network hypothesis posits that coordinated activity among interconnected nodes produces seizures. The epileptogenic zone hypothesis posits that distinct regions are necessary and sufficient for seizure generation. High-frequency oscillations, and particularly fast ripples, are thought to be biomarkers of the epileptogenic zone. We sought to test these theories by comparing high-frequency oscillation rates and networks in surgical responders and non-responders, with no appreciable change in seizure frequency or severity, within a retrospective cohort of 48 patients implanted with stereo-EEG electrodes. We recorded inter-ictal activity during non-rapid eye movement sleep and semi-automatically detected and quantified high-frequency oscillations. Each electrode contact was localized in normalized coordinates. We found that the accuracy of seizure onset zone electrode contact classification using high-frequency oscillation rates was not significantly different in surgical responders and non-responders, suggesting that in non-responders the epileptogenic zone partially encompassed the seizure onset zone(s) (P > 0.05). We also found that in the responders, fast ripple on oscillations exhibited a higher spectral content in the seizure onset zone compared with the non-seizure onset zone (P < 1 × 10−5). By contrast, in the non-responders, fast ripple had a lower spectral content in the seizure onset zone (P < 1 × 10−5). We constructed two different networks of fast ripple with a spectral content >350 Hz. The first was a rate–distance network that multiplied the Euclidian distance between fast ripple-generating contacts by the average rate of fast ripple in the two contacts. The radius of the rate–distance network, which excluded seizure onset zone nodes, discriminated non-responders, including patients not offered resection or responsive neurostimulation due to diffuse multifocal onsets, with an accuracy of 0.77 [95% confidence interval (CI) 0.56–0.98]. The second fast ripple network was constructed using the mutual information between the timing of the events to measure functional connectivity. For most non-responders, this network had a longer characteristic path length, lower mean local efficiency in the non-seizure onset zone, and a higher nodal strength among non-seizure onset zone nodes relative to seizure onset zone nodes. The graphical theoretical measures from the rate–distance and mutual information networks of 22 non- responsive neurostimulation treated patients was used to train a support vector machine, which when tested on 13 distinct patients classified non-responders with an accuracy of 0.92 (95% CI 0.75–1). These results indicate patients who do not respond to surgery or those not selected for resection or responsive neurostimulation can be explained by the epileptic network hypothesis that is a decentralized network consisting of widely distributed, hyperexcitable fast ripple-generating nodes.
Lack of clinically relevant differences in safety and pharmacokinetics after second‐dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: A population analysis
Cascino, Gregory D. , Wheless, James W. , Sperling, Michael R. , Desai, Jay , Vázquez, Blanca , Samara, Emil, Misra, Sunita N. , Carrazana, Enrique , Group, for the DIAZ.001.05 Study, Wheless, James W , Hogan, R Edward , Sperling, Michael R , Misra, Sunita N , Carrazana, Enrique , Rabinowicz, Adrian L , Cascino, Gregory D , Tarquinio, Daniel Charles , Rabinowicz, Adrián L. , Group, for the DIAZ.001.05 Study

Mayo Clinic

Epilepsia | April 4, 2022 | Volume: 63 | Issue: 7 | Pages: 1714-1723

10.1111/epi.17249 | PMID 35377464 Get It

AbstractObjectiveCurrent diazepam nasal spray labeling requires waiting 4 h before administering a second dose. The objective of the current analyses was to examine safety and pharmacokinetic profiles of second doses of diazepam nasal spray given 0−4 h after the first dose.MethodsTwo datasets were analyzed. The first, a long‐term, repeat‐dose safety study of diazepam nasal spray, compared rates of treatment‐emergent adverse events (TEAEs), serious TEAEs, and treatment‐related TEAEs for patients receiving ≥1 second dose ≤4 h versus all second doses >4 h after the first. The second was a population pharmacokinetic analysis using data from three phase 1 studies to model drug exposure when a second dose of diazepam nasal spray was administered across multiple time points (1 min−4 h) following the first dose.ResultsIn the repeat‐dose safety study, a second dose of diazepam nasal spray was administered ≤24 h after the first to treat 485 seizure clusters in 79 patients. Rates of TEAEs were similar between patients receiving ≥1 second dose in ≤4 h (89.5%, n = 38) compared with >4–24 h only (80.5%, n = 41). The most common treatment‐related TEAEs were associated with nasal discomfort, which was mild or moderate and transient. There were no reports of respiratory or cardiac depression. The pharmacokinetic simulations of second doses predicted comparable elevations of plasma diazepam concentrations with administrations across a range of intervals after the first dose (1 min−4 h).SignificanceThese data indicate that the safety and pharmacokinetic profiles of a second dose of diazepam nasal spray administered within 4 h of the first dose are consistent with those associated with current labeling. This is potentially important for patients with seizure clusters who have a recurrent seizure within 4 h of first treatment and might benefit from immediate retreatment to reduce the risk of progression to status epilepticus.
International consensus statement on allergy and rhinology: Olfaction
Patel, Zara M. , Holbrook, Eric H. , Turner, Justin H. , Adappa, Nithin D. , Albers, Mark W. , Altundağ, Aytuğ , Appenzeller, Simone , Costanzo, Richard M. , Croy, Ilona , Davis, Greg E. , Dehgani‐Mobaraki, Puya , Doty, Richard L. , Haehner, Antje , Hopkins, Claire , Hummel, Thomas , Jitaroon, Kawinyarat, Kern, Robert C. , Khanwalkar, Ashoke , Kobayashi, Masayoshi , Leopold, Donald A., Levy, Joshua M. , Marmura, Michael J. , Mclelland, Lisha, Miwa, Takaki , Moberg, Paul J., Mueller, Christian A. , Nigwekar, Sagar U. , O’Brien, Erin K. , Păunescu, Teodor G. , Philpott, Carl , Pinto, Jayant M. , Reiter, Evan R. , Schlosser, Rodney J. , Schwob, James E. , Seiden, Allen M., Smith, Timothy L. , Sowerby, Leigh J. , Tan, Bruce K. , Thamboo, Andrew , Wrobel, Bozena , Yan, Carol H. , Duffy, Valerie B , Goldstein, Bradley J , Gudis, David A , Haehner, Antje , Higgins, Thomas S , Hopkins, Claire , Huart, Caroline , Hummel, Thomas , Kern, Robert C , Khanwalkar, Ashoke R , Kobayashi, Masayoshi , Kondo, Kenji , Lane, Andrew P , Levy, Joshua M , Marmura, Michael J , O'Brien, Erin K , Paunescu, Teodor G , Pellegrino, Robert , Philpott, Carl , Roalf, David R , Rowan, Nicholas R , Schlosser, Rodney J , Schwob, James , Smith, Timothy L , Sowerby, Leigh , Yan, Carol , Holbrook, Eric H , Patel, Zara , Albers, Mark W , Adappa, Nithin D. , Gudis, David A. , Lechner, Matt , Rowan, Nicholas R. , Soler, Zachary M.

Mayo Clinic

International Forum of Allergy & Rhinology | April 3, 2022 | Volume: 12 | Issue: 4 | Pages: 327-680

10.1002/alr.22929 | PMID 35373533 Get It

Abstract Background The literature regarding clinical olfaction, olfactory loss, and olfactory dysfunction has expanded rapidly over the past two decades, with an exponential rise in the past year. There is substantial variability in the quality of this literature and a need to consolidate and critically review the evidence. It is with that aim that we have gathered experts from around the world to produce this International Consensus on Allergy and Rhinology: Olfaction (ICAR:O). Methods Using previously described methodology, specific topics were developed relating to olfaction. Each topic was assigned a literature review, evidence‐based review, or evidence‐based review with recommendations format as dictated by available evidence and scope within the ICAR:O document. Following iterative reviews of each topic, the ICAR:O document was integrated and reviewed by all authors for final consensus. Results The ICAR:O document reviews nearly 100 separate topics within the realm of olfaction, including diagnosis, epidemiology, disease burden, diagnosis, testing, etiology, treatment, and associated pathologies. Conclusion This critical review of the existing clinical olfaction literature provides much needed insight and clarity into the evaluation, diagnosis, and treatment of patients with olfactory dysfunction, while also clearly delineating gaps in our knowledge and evidence base that we should investigate further.
Abstract 10: Contraindications to Oral Anticoagulation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
O’Brien, Emily C. , Koller, Christopher , Singer, Daniel E. , Ansell, Jack , Kowey, Peter R. , Chang, Paul, Ezekowitz, Michael D. , Piccini, Jonathan P. , Holmes, DaJuanicia N. , Allen, Larry A. , Hylek, Elaine M. , Gersh, Bernard J. , Fonarow, Gregg C. , Mahaffey, Kenneth W. , Peterson, Eric D.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 6 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.6.suppl_1.a10 Get It

Background. Oral anticoagulation therapy (OAC) reduces the risk of thromboembolic events associated with atrial fibrillation (AF), yet a substantial proportion of patients with AF are not prescribed OAC. The frequencies of and factors associated with contraindications to OAC therapy in clinical practice are not well-described. Methods. We used data from the ORBIT-AF study, a national, prospective, outpatient registry of incident and prevalent AF. OAC contraindications were uniformly collected at study enrollment by site personnel. Patient and provider characteristics were compared between participants with documented OAC contraindications at baseline and those without OAC contraindications. Results. From June 2010 to August 2011, 10124 patients ≥18 years old with electrocardiographically documented AF were enrolled at 176 practices. Of these, 1409 (13.9%) had OAC contraindications documented at the baseline visit: prior bleed (26.2%), patient refusal/preference (26.0%), high bleeding risk (22.6%), frequent falls/frailty (16.6%), other (11.9%), need for dual antiplatelet therapy (9.8%), unable to adhere/monitor warfarin (5.7%), comorbid illness (5.0%), prior intracranial hemorrhage (4.7%), allergy (2.3%), occupational risk (0.8%), and pregnancy (0.2%). Compared to patients without contraindications, those with contraindications had higher stroke risk (CHADS2>2) and were older, more likely to be female, more likely to be seen by a cardiologist and less likely to be seen by an electrophysiologist (Table 1). Among those patients with reported contraindications, 28.4% were taking warfarin. Conclusions. Contraindications to OAC therapy among AF patients are common and often due to high bleeding risk. Furthermore, many patients with reported contraindications are taking warfarin, suggesting that many contraindications to warfarin therapy are minor, relative, or temporary.
Characteristics of Post-ICU and Post-COVID Recovery Clinics in 29 U.S. Health Systems
Danesh, Valerie, Boehm, Leanne M., Eaton, Tammy L., Arroliga, Alejandro C., Mayer, Kirby P., Kesler, Shelli R., Bakhru, Rita N., Baram, Michael, Bellinghausen, Amy L., Biehl, Michelle, Dangayach, Neha S., Goldstein, Nir M., Hoehn, K. Sarah, Islam, Marjan, Jagpal, Sugeet, Johnson, Annie B., Jolley, Sarah E., Kloos, Janet A., Mahoney, Eric J., Maley, Jason H., Martin, Sara F., McSparron, Jakob I., Mery, Marissa, Saft, Howard, Santhosh, Lekshmi, Schwab, Kristin, Villalba, Dario, Sevin, Carla M., Montgomery, Ashley A., Boehm, Leanne M. , Eaton, Tammy L. , Santhosh, Lekshmi , Danesh, Valerie , Mayer, Kirby P. , Arroliga, Alejandro C., Mayer, Kirby P., Kesler, Shelli R., Bakhru, Rita N., Baram, Michael, Bellinghausen, Amy L., Biehl, Michelle, Dangayach, Neha S., Goldstein, Nir M., Hoehn, K. Sarah, Islam, Marjan, Jagpal, Sugeet, Johnson, Annie B., Jolley, Sarah E., Kloos, Janet A., Mahoney, Eric J., Maley, Jason H., Martin, Sara F., McSparron, Jakob I., Mery, Marissa , Saft, Howard, Schwab, Kristin, Villalba, Darío Salvador , Sevin, Carla M., Montgomery, Ashley A.

Mayo Clinic

Critical Care Explorations | March 9, 2022 | Volume: 4 | Issue: 3 | Pages: e0658

10.1097/cce.0000000000000658 | PMID 35291316 Get It

OBJECTIVES: The multifaceted long-term impairments resulting from critical illness and COVID-19 require interdisciplinary management approaches in the recovery phase of illness. Operational insights into the structure and process of recovery clinics (RCs) from heterogeneous health systems are needed. This study describes the structure and process characteristics of existing and newly implemented ICU-RCs and COVID-RCs in a subset of large health systems in the United States. DESIGN: Cross-sectional survey. SETTING: Thirty-nine RCs, representing a combined 156 hospitals within 29 health systems participated. PATIENTS: None. INTERVENTIONS: None. MEASUREMENT AND MAIN RESULTS: RC demographics, referral criteria, and operating characteristics were collected, including measures used to assess physical, psychologic, and cognitive recoveries. Thirty-nine RC surveys were completed (94% response rate). ICU-RC teams included physicians, pharmacists, social workers, physical therapists, and advanced practice providers. Funding sources for ICU-RCs included clinical billing (n = 20, 77%), volunteer staff support (n = 15, 58%), institutional staff/space support (n = 13, 46%), and grant or foundation funding (n = 3, 12%). Forty-six percent of RCs report patient visit durations of 1 hour or longer. ICU-RC teams reported use of validated scales to assess psychologic recovery (93%), physical recovery (89%), and cognitive recovery (86%) more often in standard visits compared with COVID-RC teams (psychologic, 54%; physical, 69%; and cognitive, 46%). CONCLUSIONS: Operating structures of RCs vary, though almost all describe modest capacity and reliance on volunteerism and discretionary institutional support. ICU- and COVID-RCs in the United States employ varied funding sources and endorse different assessment measures during visits to guide care coordination. Common features include integration of ICU clinicians, interdisciplinary approach, and focus on severe critical illness. The heterogeneity in RC structures and processes contributes to future research on the optimal structure and process to achieve the best postintensive care syndrome and postacute sequelae of COVID outcomes.